FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers

This article was originally published here

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from

The post FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply